CAMBRIDGE, Mass., Nov. 22, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 28th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City, NY on Wednesday, November 30, 2016, at 1:00pm Eastern time.
The presentation will be webcast live and may be accessed from the news and events section of the Vericel website: www.vcel.com/events.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing two additional cell products. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel T is an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Instagram Outage Disrupts Thousands of U.S. Users
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 



